Nucleic Acid Isolation, Quantitation, and Purification - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The nucleic acid isolation, quantitation, and purification market size is expected to grow from USD 5.59 billion in 2025 to USD 6.11 billion in 2026 and is forecast to reach USD 9.55 billion by 2031 at 9.33% CAGR over 2026-2031. This report is Segmented by Technology (Column-Based Purification, and More), Product (Kits & Reagents, Equipment, and Other Products), Application (Total RNA Isolation & Purification, and More), End-User (Hospitals, and More), Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Nucleic Acid Isolation, Quantitation, And Purification Market Trends and Insights

Surge in Clinical-Grade NGS Demand

Growing use of NGS in oncology raises extraction specifications for formalin-fixed and liquid biopsy samples. Labcorp reports threefold better DNA quality from FFPE tissue when using focused acoustics instruments that minimize fragmentation. Liquid biopsy assays require purification systems able to enrich circulating tumor DNA constituting under 1% of total cell-free DNA. Suppliers therefore price premium kits that safeguard integrity, reduce PCR inhibitors and match regulatory documentation for clinical accreditation.

National Genomics Initiatives

Government sequencing programs keep order volumes stable by standardizing high-throughput protocols. Australia’s Genomics Health Futures Mission has committed USD 500.1 million for more than 200 000 citizens, fuelling demand for automated bead platforms that can process diverse blood and tissue inputs. Similar multi-omics efforts in the US and UK reinforce global harmonization, encouraging vendors to ship pre-validated chemistries that deliver consistent yield across distributed sites.

High Instrument & Reagent Costs

Automated extractors can cost USD 100 000-500 000 and consumables add USD 10-50 per sample, limiting adoption in smaller labs. Low-cost alternatives such as filter paper-spin columns have reduced per-sample expense while retaining adequate purity. Some vendors now market reusable resin cartridges and long-life beads to trim operating budgets.

Other drivers and restraints analyzed in the detailed report include:

• Increased R&D Funding in Molecular Biology
• Microfluidic Extraction for PoC Devices
• Low Penetration in Emerging Markets

Segment Analysis

Magnetic beads delivered the largest contribution to the nucleic acid isolation and purification market size, with 51.60% of 2025 revenue and an 11.06% growth trajectory to 2031. This format binds DNA or RNA to silica-coated beads under chaotropic salts, then allows magnet-assisted washing that avoids centrifugation. Workflow speed improves further with formulations such as Cytiva’s guanidinium-thiocyanate chemistry, which inhibits nucleases while ensuring high recovery.

Column-based kits still serve manual setups because their cost per extraction remains lower, yet adoption declines in high-throughput labs. New bead protocols like SHIFT-SP reach near-complete recovery inside seven minutes, supporting clinical turnaround demands. Their compatibility with liquid handlers anchors their long-term advantage.

Kits and reagents secured 47.85% of 2025 sales, reflecting routine replenishment cycles in diagnostics and research. However, equipment revenue grows fastest at 11.32% CAGR as laboratories invest in robotic extractors that enforce standardization. Beckman Coulter’s OptiMATE Gradient Maker cut ultracentrifugation from three days to six hours, underscoring how instrumentation improves virus-vector workflows.

Spectrophotometers and fluorometers meet stricter quality-control rules that accompany clinical sequencing. Revvity’s chemagic 360 spans 50 µl to 18 ml inputs, pairing software tracking with barcode integration for audit readiness. Consumables such as tips and magnetic rods keep recurring revenues resilient.

Complete Report Scope:

• By Technology
  • Column-based Purification
  • Magnetic Bead-based Purification
  • Reagent-based Purification
• By Product
  • Kits & Reagents
    • NA Isolation & Purification Kits
    • NA Quantitation Kits
      • DNA Quantitation Kits
      • RNA Quantitation Kits
  • Equipment
    • NA Isolation & Purification Instruments
    • NA Quantitation Instruments
      • Spectrophotometer
      • Fluorometer
  • Other Products
• By Application
  • Total RNA Isolation & Purification
  • mRNA Isolation & Purification
  • microRNA Isolation & Purification
  • Plasmid DNA Isolation & Purification
  • Genomic DNA Isolation & Purification
  • Blood DNA Isolation & Purification
  • PCR Clean-up
  • Biobanking
  • Clinical Research
  • Forensics
  • Drug Development
  • Other Applications
• By End-user
  • Hospitals
  • Academia
  • Pharmaceutical / Biotechnology Industry
  • CRO
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 41.95% of the nucleic acid isolation and purification market in 2025 thanks to NIH-funded translational genomics, dense biotech clusters and an FDA decision to reclassify high-risk in-vitro diagnostics to Class II, trimming approval timelines. The United States anchors sales, while Canadian and Mexican labs enlarge regional throughput with cross-border clinical-trial activity.

Europe follows with harmonized regulatory frameworks that ease multi-nation research. Germany, the UK and France command instrument procurements driven by established pharmaceutical manufacturing. Wellcome Trust funding of population biobanking sustains demand for automated bead platforms that ensure data integrity across consortium sites. Emphasis on data privacy increases sales of software-embedded extractors that log sample identity.

Asia-Pacific is projected to post a 10.12% CAGR through 2031, fastest worldwide. China’s pharmaceutical policy backs local nucleic acid drug production, fostering large reagent orders, while India’s cost-efficient gene-therapy initiatives encourage adoption of flexible microfluidic kits. Australia’s Genomics Health Futures Mission adds institutional budgets for high-throughput sequencers and extraction robots. Japan and South Korea emphasize precision medicine, lifting demand for high-purity, multi-analyte purification consumables.

List of Companies Covered in this Report:

• Agilent Technologies
• Illumina
• QIAGEN
• Bio-Rad Laboratories
• Danaher Corp. (Beckman Coulter)
• GE Healthcare
• Roche
• Merck
• Thermo Fisher Scientific
• Takara Holdings
• Promega Corp.
• Revvity (PerkinElmer)
• Biovision
• Zymo Research
• New England Biolabs
• Norgen Biotek
• Omega Bio-tek
• Analytik Jena
• Sartorius
• Aurora Biomed

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support